Authors do not have financial interest with any of the products named in this study and companies that directly compete with products named in this manuscript.
Favourable response to infliximab in a case of bilateral refractory Mooren's ulcer
Version of Record online: 18 DEC 2007
Clinical & Experimental Ophthalmology
Volume 35, Issue 9, pages 871–873, December 2007
How to Cite
Fontana, L., Parente, G., Neri, P., Reta, M. and Tassinari, G. (2007), Favourable response to infliximab in a case of bilateral refractory Mooren's ulcer. Clinical & Experimental Ophthalmology, 35: 871–873. doi: 10.1111/j.1442-9071.2007.01609.x
- Issue online: 18 DEC 2007
- Version of Record online: 18 DEC 2007
- Received 8 April 2007; accepted 21 August 2007.
- corneal perforation;
- Mooren's ulcer;
- tumour necrosis factor-alpha
A woman with progressive bilateral Mooren's ulcer developed recurrent corneal perforations and melting requiring tectonic grafts, despite conventional immunosuppressant therapy. Following treatment with infliximab, an anti-tumour necrosis factor agent, the patient showed marked reduction in conjunctival inflammation and no further recurrence of corneal thinning and perforation during 2-year follow up on maintaining treatment.